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Objectives: We aimed to compare perinatal outcomes of oligohydramnios or fetal growth 
restriction with normal amniotic fluid index and fetal growth in preeclampsia and to 
compare the outcomes of only oligohydramnios, only fetal growth restriction and 
oligohydramnios with fetal growth restriction preeclamptic groups. 
Material and methods: A total of 743 preeclamptic patients were evaluated between June 
2016 and 2020. Patients were divided into two groups: preeclampsia with oligohydramnios 
or fetal growth restriction (n = 237) and preeclampsia with normal amniotic fluid index and 
fetal growth (n = 506). Then, the first group was divided subgroups as only 
oligohydramnios (n = 55), only fetal growth restriction (n = 125) and oligohydramnios with 
fetal growth restriction (n = 57). Demographic characteristics and perinatal outcomes were 
recorded.  
Results: Gestational age at delivery (p < 0.001), birth weight (p < 0.001), Apgar scores (p 
< 0.001) and eclampsia (p < 0.001) were lower whereas impaired doppler findings (p < 
0.001), cesarean rates (p < 0.001), preterm delivery (p < 0.001), abruptio placenta (p < 
0.001), acute fetal distress (p < 0.001), RDS (p < 0.001), NICU requirement (p < 0.001) 
and neonatal death (p < 0.001) were higher in oligohydramnios or fetal growth restriction 
preeclamptic group. In subgroup analysis, there were differences between three groups 
according to the gestational age (p < 0.001), cesarean rates (p = 0.002), preterm delivery (p 
< 0.001), intensive care unit requirement (p = 0.039), birth weight (p < 0.001), Apgar 
scores (p < 0.001), RDS (p < 0.001) and NICU requirement (p < 0.001). In pairwise 
comparison, there was significant difference between only oligohydramnios and only fetal 
growth restriction group and between only oligohydramnios and oligohydramnios with 
fetal growth restriction group according to birth weight, Apgar scores, preterm delivery and 
cesarean rates, presence of RDS, maternal and neonatal intensive care unit requirement. No 
significant difference was detected between only fetal growth restriction group and 
oligohydramnios with fetal growth restriction group in terms of all parameters.  
Conclusions: We suggest that patients with only oligohydramniosis have more favorable 
pregnancy outcomes than pregnants with only fetal growth restriction and coexistence of 
two conditions in preeclamptic patients. We claim that it could be appropriate to 
recommend close monitorization in preeclamptic patients with only fetal growth restriction 
and oligohydramniosis and fetal growth restriction.  




Preeclampsia, defined as the presence of hypertension in after late second trimester 
accompanied by proteinuria, maternal organ dysfunction or uteroplacental dysfunction, 
complicates approximately 2.5–8% of the pregnancies [1, 2]. Preeclampsia has catastrophic 
consequences such as fetal and maternal death. Moreover, it is tightly related to adverse 
perinatal outcomes including increased cesarean section rate, low Apgar scores, 
prematurity, placental abruption, HELLP (hemolysis, elevated liver enzymes, low platelets) 
syndrome, eclampsia, disseminated intravascular coagulation and increased maternal/fetal 
intensive care unit requirement [3].  
Fetal growth restriction can be defined as an inadequate fetal growth compared to 
the expected growth potential based on the estimated fetal weight and/or abdominal 
circumference after adjusted for gestational age, race and gender [4]. It is related to 
perinatal mortality and morbidity. Furthermore, it contributes to chronic diseases such as 
hypertensive disorders [5]. In previous studies, preeclamptic patients have increased odds 
of fetal growth restriction and fetal growth restriction is claimed to be the indicator of 
severity of preeclampsia [6].   
Amniotic fluid is a liquid surrounding the fetus and providing optimal environment 
for fetal development of fetal respiratory, gastrointestinal, musculoskeletal and urinary 
system [7]. Normal amniotic fluid index varies between 5–24 centimeters and 
oligohydramnios is defined as an amniotic fluid index below five centimeters [8]. 
Oligohydramnios can lead to fetal growth restriction, pulmonary hypoplasia, cord 
compression, low Apgar scores, fetal mortality and increased cesarean section rates [9–11]. 
Oligohydramnios could be found as a concomitant condition in 10–30% of preeclamptic 
patients with or without fetal growth restriction [12].  
Placental insufficiency is claimed to have a key role in preeclampsia. Similarly, 
fetal growth restriction could result from abnormal placentation leads to inadequate 
uteroplacental blood flow [13]. Another condition which arises from placental insufficiency 
is oligohydramnios. Therefore, preeclampsia, fetal growth restriction and oligohydramnios 
are the conditions rising from the same etiopathogenesis named as placental insufficiency 
[14]. Thus, the clinical conditions are in relationship with each other and affects adverse 
perinatal outcomes. However, there are data in the literature evaluating the effect of 
oligohydramnios and fetal growth restriction together in preeclampsia, there is no evidence 
about the separate roles of oligohydramnios and fetal growth restriction in adverse 
pregnancy outcomes in preeclampsia.   
To the best of our knowledge, it is the first study searching the perinatal outcomes 
of preeclamptic patients by dividing the parturients with only oligohydramnios, only fetal 
growth restriction and oligohydramnios with fetal growth restriction. In this study, we 
aimed to compare the perinatal outcomes of oligohydramnios or fetal growth restriction 
preeclamptic group with normal amniotic fluid index and fetal growth preeclamptic group 
and to compare the outcomes of only oligohydramnios, only fetal growth restriction and 
oligohydramnios with fetal growth restriction preeclamptic groups. 
 
MATERIAL AND METHODS 
This retrospective study was performed at the obstetrics and gynecology department 
of a university affiliated research and training hospital between June 2016 and June 2020. 
At admission, informed consent for being a participant of a study is routinely taken from all 
participants. The study was approved by the local Ethics Committee of University of 
Health Sciences, Bursa Yuksek Ihtisas Research and Training Hospital with a decision 
number of 2011-KAEK-25 2020/06-13.   
Study Population 
The study included 743 preeclamptic patients who admitted to our clinic for regular 
antenatal visits and gave a birth in our hospital between June 2016 and June 2020. Initially, 
preeclamptic patients were divided into two groups as: preeclampsia with oligohydramnios 
or fetal growth restriction (n = 237) and preeclampsia with normal amniotic fluid index and 
fetal growth (n = 506). After then, preeclampsia with oligohydramnios or fetal growth 
restriction group were divided into three subgroups as: only oligohydramnios (n = 55), only 
fetal growth restriction (n = 125) and oligohydramnios with fetal growth restriction (n = 
57) group.  
Demographic characteristics of the patients, gestational age at delivery, Doppler 
ultrasonography findings, delivery mode, birth weight, perinatal complications such as 
placental abruption, acute fetal distress, respiratory distress syndrome (RDS), HELLP 
syndrome, eclampsia, neonatal death, APGAR scores of neonates and maternal/fetal 
intensive care unit requirement were obtained from hospital medical records.  
Exclusion criteria of the study were as follows: having unregular antenatal visit, 
uterine malformations, endocrine disorders such as diabetes mellitus and thyroid disorders, 
hematologic disorders leading thrombocytopenia, intrauterine infectious or inflammatory 
conditions, history of cardiac diseases, multiple pregnancy, congenital fetal anomalies, post 
term pregnancy, premature rupture of membranes, any hypertensive disorders except 
preeclampsia, pregestational diabetes mellitus, kidney or liver dysfunction leading to 
increased creatinine and transaminase levels, maternal drug use including angiotensin 
converting enzyme inhibitor or nonsteroid anti-inflammatory drugs, smoking and tobacco 
use.  
Patients were followed with Umbilical artery Doppler velocimetry, nonstress tests 
and biophysical profiles after the diagnosis of fetal growth restriction. To improve preterm 
neonatal outcomes antenatal corticosteroids were applied before 33 6/7 weeks and 
neuroprotective magnesium sulfate was administered in cases which were delivered before 
32nd gestational weeks. Additionally, we ordered antenatal corticosteroids for cases 
between 34–37 weeks of gestation who are at risk of preterm delivery within a week. No 
supplemental nutritional or dietary intake were ordered for these cases. Delivery mode was 
decided according to the obstetric indications and optimum delivery time was decided due 
to the gestational week and the cause of fetal growth restriction.  
Statistical Analysis 
Shapiro Wilk test was used to determine the normality of distribution. Mann 
Whitney U test was performed to compare perinatal outcomes of oligohydramnios or fetal 
growth restriction preeclamptic group with normal amniotic fluid index and fetal growth 
preeclamptic group for continuous variables while chi-square test was used to compare 
categorical variables between two groups. Variables were expressed as median (minimum-
maximum) for continuous variables and percentages for categorical variables. Kruskal 
Wallis test was carried out to compare patients with only oligohydramnios, only fetal 
growth restriction and oligohydramnios with fetal growth restriction preeclamptic groups. 
Furthermore, Mann Whitney U test was used for pairwise comparison. Categorical 
variables were compared with Chi-Square and Fisher’s exact test. The level of significance 
was set at α = 0.05. Statistical analysis of the study was performed by using SPSS Version 




 Maternal demographic features and maternal outcomes of the study group were 
presented in Table 1. There was no statistically significant difference between 
oligohydramnios or fetal growth restriction preeclamptic group and preeclampsia with 
normal amniotic fluid index and fetal growth groups in terms of age, parity, HELLP 
syndrome and adult intensive care unit requirement. Oligohydramnios or fetal growth 
restriction preeclamptic group had statistically higher rates of impaired Doppler findings as 
compared to normal amniotic fluid index and fetal growth preeclamptic group (p < 0.001). 
According to maternal outcomes, gestational age at delivery and presence of eclampsia was 
significantly lower (p < 0.001) whereas cesarean section rates, the frequency of preterm 
delivery (p < 0.001), abruptio placenta (p < 0.001) and acute fetal distress (p < 0.001) were 
higher in oligohydramnios or fetal growth restriction preeclamptic group.  
 Neonatal outcomes of the study group were shown in Table 2. There was 
statistically significant difference with regard to all neonatal outcomes between two groups. 
While birthweight (p < 0.001), Apgar scores of first minutes (p < 0.001), Apgar scores of 
fifth minutes (p < 0.001) were significantly lower in oligohydramnios or fetal growth 
restriction preeclamptic group, the rates of RDS (p < 0.001), NICU requirement (p < 0.001) 
and neonatal death (p < 0.001) were higher than normal amniotic fluid index and fetal 
growth preeclampsia group. 
 Maternal demographic features and maternal outcomes of only oligohydramnios, 
only fetal growth restriction and oligohydramnios with fetal growth restriction groups were 
demonstrated in Table 3. In subgroup analysis, no significant difference was found between 
subgroups in terms of age, parity, the frequency of impaired doppler findings, abruptio 
placenta, acute fetal distress, HELLP syndrome and eclampsia. There was difference 
between three groups according to the gestational age at delivery (p < 0.001), cesarean 
section rates (p = 0.002), preterm delivery (p  < 0.001) and intensive care unit requirement 
(p = 0.039).     
 Neonatal outcomes of the subgroups were shown in Table 4. There was 
statistically significant difference between three groups according to birth weight (p < 
0.001), Apgar scores of first minutes (p < 0.001), Apgar scores of fifth minutes (p < 0.001), 
RDS (p < 0.001) and NICU requirement (p < 0.001).  
 Pairwise comparison of groups were shown in Table 5. There was statistically 
significant difference between only oligohydramnios and only fetal growth restriction 
group and between only oligohydramnios and oligohydramnios with fetal growth 
restriction group with regard to birth weight, Apgar scores of first and fifth minutes, 
preterm delivery and cesarean section rates, presence of RDS, maternal and neonatal 
intensive care unit requirement. No significant difference was detected between only fetal 
growth restriction group and oligohydramnios with fetal growth restriction group in terms 
of all parameters. 
 
DISCUSSION 
 The main findings of the study were as follows: 1. Preeclamptic patients with 
oligohydramnios or fetal growth restriction had higher rates of impaired Doppler findings, 
lower gestational age at delivery, birthweight, Apgar scores, higher cesarean section rates, 
frequency of preterm delivery, abruptio placenta, acute fetal distress, RDS, NICU 
requirementand neonatal death as compared to normal amniotic fluid index and fetal 
growth preeclamptic group; 2. In subgroup analysis, there was significant difference 
between only oligohydramnios and only fetal growth restriction group and between only 
oligohydramnios and oligohydramnios with fetal growth restriction group with regard to 
birth weight, Apgar scores of first and fifth minutes, preterm delivery and cesarean section 
rates, presence of RDS, maternal and neonatal intensive care unit requirement. No 
significant difference was detected between only fetal growth restriction group and 
oligohydramnios with fetal growth restriction group in terms of all parameters. 
Preeclampsia, one of the most common cause of perinatal mortality and morbidity, 
complicates nearly 4–5% of pregnancies among worldwide [15]. Although many etiologic 
factors were claimed to play a role in the etiopathogenesis of preeclampsia, the main 
underlying mechanism remains unclear. Abnormal placentation, oxidative stress, immune 
mechanisms, endothelial dysfunction and imbalance in angiogenesis are some of the 
mechanisms of preeclampsia. Whereas researchers hypothesized that impaired placentation 
has the key role in preeclampsia in 1960, the disease is accepted to occur in terms of both 
abnormal placentation followed by maternal vascular dysfunction in recent times [16]. 
In the literature, it has been shown that the number placental infarcts suggesting 
placental hypoperfusion and ischaemia are increased in preeclamptic women [17]. In a 
study evaluating placental bed samples, the authors demonstrated increased thrombotic 
occlusion in vessels and lipophage infiltration in preeclampsia as compared to other 
hypertensive conditions [18]. In another study, the spiral arteries in placental bed samples 
were found to be narrowed in preeclampsia than normal pregnancies [19]. Moreover, the 
severity of preeclampsia was shown to be correlated with the atherosis and sclerosis of 
arterial structures, fibrin deposition and infarction leading to placental insufficiency [20].  
Another remarkable issue about placental insufficiency is the relationship between 
abnormal placentation and fetal growth restriction accompanying preeclampsia. Recent 
study has shown more common major defects in spiral arteries in preeclamptic women 
when it is complicated with fetal growth restriction [21]. 
Fetal growth restriction is defined as estimated fetal weight or abdominal 
circumference below 10th percentile and/or abnormal Doppler waveforms by current 
guidelines. Fetal growth restriction could occur due to the maternal, fetal or placental 
factors. Likewise, to preeclampsia, reduced utero placental blood flow named as placental 
insufficiency is the main contributor of fetal growth restriction. Furthermore, it is clearly 
known that impaired secretion of proangiogenic factors, enhanced secretion of soluble fms-
like tyrosine kinase-1, placental infarction and decidual vasculopathy are the etiologic 
mechanisms both in preeclampsia and fetal growth restriction [22]. 
Oligohydramnios is another condition that is related with placental insufficiency.  
In a study of Rabinovich, the possible mechanism of oligohydramnios in preeclampsia is 
reported to be placental insufficiency [13]. Placental insufficiency leads to shunt the blood 
flow from nonessential organs such as kidneys to the essential ones such as the brain. This 
condition causes reduced renal flow and urine output which consequently results in 
oligohydramnios [23]. 
The aforementioned above preeclampsia, fetal growth restriction and 
oligohydramnios are tightly related entities with placental insufficiency. There are many 
studies in the literature searching the placental pathologies or pregnancy outcomes of those 
conditions separately or concomitantly. In contrast there is only a few data in the literature 
evaluating the effect of oligohydramnios and fetal growth restriction together in 
preeclampsia.  
Balogun et al. [24] claimed that preterm preeclamptic parturients with fetal growth 
restriction have higher composite maternal and neonatal morbidity risk than appropriate for 
gestational age cases. Similarly, Haddad et al. [25] showed that severe fetal growth 
restriction is associated with increased fetal death risk while maternal complications were 
not different in preterm severe preeclampsia cases.  
 In the study of Rabinovich et al. [13] 81 preterm preeclamptic patients with 
oligohydramnios and 81 preterm preeclamptic patients with normal amniotic fluid were 
compared. They found that birth weights were lower, fetal distress during labor was more 
frequent, neonatal anemia was more common and hospitalization in NICU was longer in 
oligohydramnios group. In addition to this, they reported that oligohydramnios is an 
independent risk factor for early neonatal morbidity in preterm preeclamptic patients. In 
contrast, in a study of Barrilleaux et al. [26] searching preterm preeclamptic patients with 
HELLP syndrome, they reported that amniotic fluid index is a poor predictor for neonatal 
outcome. Rabie et al. [27] claimed that oligohydramnios was related to lower birth weight 
in preterm preeclampsia while no significant association was found for cesarean section 
rates and NICU admission. 
 There are conflicting results for the relationship between oligohydramnios and 
adverse perinatal outcomes in pregnancies with fetal growth restriction [28]. However, no 
association was reported in some studies, Sasahara et al., showed that reduced amniotic 
fluid is a predictor for cerebral palsy and mortality in preterm fetal growth restriction cases 
[29]. Spinollo et al. [30] showed that reduced amniotic fluid index is correlated with the 
features of histopathological signs of placental insufficiency in fetal growth restriction. In 
another study evaluating the role of oligohydramnios in fetal growth restriction 
pregnancies, oligohydramnios was found to be associated with fetal hypoxia, fetal distress 
and abnormal Doppler findings [31–33].  
 In this study, we searched for the perinatal outcomes of preeclamptic patients by 
dividing the parturients with only oligohydramnios, only fetal growth restriction and 
oligohydramnios with fetal growth restriction for the first time. We compared the perinatal 
outcomes of oligohydramnios or fetal growth restriction preeclamptic group with normal 
amniotic fluid index and fetal growth preeclamptic group and compared the outcomes of 
only oligohydramnios, only fetal growth restriction and oligohydramnios with fetal growth 
restriction preeclamptic groups. We showed that oligohydramnios or fetal growth 
restriction preeclamptic group has worsened perinatal outcomes than normal amniotic fluid 
and fetal growth preeclamptic patients. Moreover, we found that preeclamptic paturients 
with only oligohydramnios have favorable pregnancy outcomes as compared to only fetal 
growth restriction or coexistence of these conditions. It is known that preeclampsia can 
affect amniotic fluid volume by changing transplacental and transmembrane water 
dynamics while redistribution of blood flow to essential organs and placental vascular 
resistance are more prominent mechanism in fetal growth restriction. Thus, it may not be 
amazing that preeclamptic patients with fetal growth restriction have worse pregnancy 




 Oligohydramniosis and fetal growth restriction are entities arising from same 
etiopathogenesis. It is known that pregnancies with oligohydramniosis and fetal growth 
restriction have worsened outcomes. Here, we suggest that patients who have only 
Oligohydramniosis have more favorable pregnancy outcomes as compared to parturients 
with only fetal growth restriction and coexistence of two conditions in preeclamptic 
patients. So, we claim that it could be appropriate to recommend close monitorization in 
preeclamptic patients with only fetal growth restriction and oligohydramniosis and fetal 
growth restriction.  
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Table1. Maternal features and outcomes of the study group 
 Reduced amniotic 
volume or fetalgrowth 
(n = 237) 
Normal 
Amniotic Fluid 
and fetal growth 










Table 2. Neonatal outcomes of the study group 
 Oligohydramnios or 
fetal growth 
(n = 237) 
Normal Amniotic Fluid 
and fetal growth 
(n  =506) 
 
p-value 
Birthweight (week) 1680 (405–4780) 2910 (560–4720) < 0.001a 
Apgar 1st minute 6 (0–9) 8 (0–9) < 0.001a 
Apgar 5th minute 8 (0–10) 9 (0–10) < 0.001a 
RDS (n, %) 120 (50.6%) 72 (14.2%) < 0.001b 
NICU (n, %) 157 (66.2%) 100 (19.8%) < 0.001b 
Age (years) 26 (17–41) 26 (16–41) 0.081a 
Parity (n) 2 (0–7) 2 (0–8) 0.246a 
Impaired Doppler findings 
(n, %) 
20 (8.4%) 11 (2.2%) < 0.001b 
Gestational age at delivery 
(week) 
34 (24–39) 37 (27–41) < 0.001a 
Cesarean section (n, %) 129 (54.4%) 190 (37.5%) < 0.001b 
Preterm delivery (n, %) 185 (78.1%) 214 (42.3%) < 0.001b 
Abruptio placenta (n, %) 12 (5.1%) 17 (3.4%) < 0.001b 
Acute fetal distress (n, %) 73 (30.8%) 97 (19.2%) < 0.001b 
HELLP syndrome (n, %) 14 (5.9%) 17 (3.4%) 0.106b 
Eclampsia (n, %) 6 (2.5%) 20 (4%) < 0.001b 
Intensive care unit 
requirement (n, %) 
27 (11.4%) 41 (8.1%) 0.147b 
Neonatal death (n, %) 18 (7.6%) 12 (2.4%) < 0.001b 
Data are expressed as median (minimum: maximum) or n (%); a — Mann-Whitney U test; 
b — Chi-Square test 
 
 


















Age (years) 26 (17–41) 26 (17–41) 26 (17–41) 0.556b 
Parity (n) 2 (0–5) 2 (0–7) 2 (0–5) 0.570
b 
Impaired Doppler 



















Cesarean section (n, 
%) 
19 (34.5%) 73 (58.4%) 37 
(64.9%) 
0.002a 
Preterm delivery (n, 
%) 




0 (0%) 7 (5.6%) 5 (8.8%) 0.070
c 
Acute fetal distress 
(n, %) 





1 (1.8%) 8 (6.4%) 5 (8.8%) 0.290
c 
Eclampsia (n, %) 1 (1.8%) 3 (2.4%) 2 (3.5%) 0.868
c 
Intensive careunit 









Data are expressed as median (minimum: maximum) or n (%); a — Chi-Square test; b —
Kruskal Wallis test; c — FisherExact 
 












and fetal growth 




Birth weight (week) 
2460 (610–4780) 1520 (405–3360) 1390 (525–2350) < 0.001
a 
Apgar 1st minute 
8 (3–9) 6 (0–9) 6 (0–8) < 0.001
a 
Apgar 5th minute 
9 (4–10) 7 (0–10) 7 (0–9) < 0.001
a 
RDS (n, %) 16 (29.1%) 69 (55.2%) 35 (61.4%) 0.001b 
NICU (n, %) 25 (45.5%) 89 (71.2%) 43 (75.4%) 0.001b 
Neonatal death n, %) 1 (1.8%) 12 (9.6%) 5 (8.8%) 0.176b 
Data are expressed as median (minimum: maximum) or n (%); a — Mann-Whitney U test; 
b — Chi-Squaretest 
 
 
Table 5. Pairwise comparison of subgroups 
 P = 1-2 P = 1-3 P = 2-
3 
Birth weight (week) < 
0.001 
0.001 0.288 










Preterm delivery (n,%) < 
0.001 
0.001 0.286 
Cesarean section (n,%) 0.003 0.001 0.405 
RDS (n,%) 0.001 0.001 0.433 
NICU (n, %) 0.001 0.001 0.552 
Intensive care unit requirement (n, %) 0.011 0.032 0.948 
 
 
 
